Tractography-Guided Nerve-Sparing in Prostate Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorMassimo Valerio

About this trial

Radical prostatectomy (RP) is an effective treatment leading to a high rate of oncological control. However, despite advances in robot-assisted RP, the genito-urinary function, especially erectile function and urinary continence, may be significantly impaired after surgery.

Our study aims to characterize and map the nerve fibers surrounding the prostate before and after surgery using diffusion tensor magnetic resonance imaging (DTI), a non-invasive magnetic resonance imaging (MRI) technique. This relatively new technology, combined with the 3D tractography software, will allow us to create a personalized 3D model of the periprostatic nerves. This virtual model will help us to assess the nerve bundles and how the surgery impacts their integrity. DTI and 3D reconstruction will be performed before and 6 months after surgery.

The pre-surgery 3D virtual model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organization. At the post-surgery level, the 3D virtual model of the nerve bundles will be compared to the pre-surgery model. Post-treatment changes at 6 months may help assess nerve preservation and their relationship with erectile (dys)function.

The main questions the clinical study aims to answer are:

1. Post-treatment DTI-Tractography parameter changes at 6 months may help assess nerve recovery and their relationship with erectile (dys)function (PROMs - IIEF-5 score) 2. Post-treatment DTI-Tractography parameter changes at 6 months may help assess their relationship with urinary function 3. At the post-surgery level, the 3D virtual model of the nerve bundles will be compared to the pre-surgery 3D model. 4. The pre-surgery 3D virtual model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organization (mean surgery time, surgeon feedback assessment, etc., will be evaluated.) Tumor location based on the 3D model will also be explored.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histological confirmed diagnosis of prostate cancer (PCa) based on prostate biopsy

Multidisciplinary indication for radical prostatectomy, validated by the Urology Tumor Board

No prior treatment of prostate cancer

Capacity to provide informed consent

Disqualifiers

Unwillingness to participate.

Pre-existing impaired sexual function before surgery (IIEF5 Score of ≤21)

Diagnosis of neuropathy

Inability to comply with study procedure (e.g. due to language barriers, psychological disorders, dementia, anxiety/claustrophobia during pelvic MRI etc.) or medical contraindications to MRI

Trial design

Design model

Single group

Treatments tested in this trial

  • Prostate Tractography for Nerve-Sparing

    Procedure/Surgery

    Tractography will be performed according to established best practices. To create the 3DVM, a high-performance workstation equipped with a high-end GPU will be used. ROI placement for nerve tractography and segmentation tasks will be performed semi-automatically using a previously trained nnU-Net pipeline. All inference will be strictly performed locally on this dedicated machine resulting in 4 segment masks (Prostate, Urethra, Index Lesion, Seminal Vesicles) that will be manually reviewed and corrected. The subsequent reconstructed Tractography bundles will be added to create the 3DTVM. The 3DTV model will be overlaid and mapped onto the intraoperative surgical view, providing the surgeon with a visual guide of the nerve fiber organizations (mean surgery time, surgeon feedback etc will be evaluated.)

Treatment groups

23 Participants
are divided into 1 treatment group
Group A: Participants with prostate cancer undergoing robot-assisted radical prostatectomy.Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Evaluation of erectile function at 6-month.

Imaging versus Patient-Reported Outcome Measure (PROM).

Time frame
From surgery (day 0) and at the 6-month follow-up (day 180).

Secondary outcomes

1

1. Evaluation of urinary function at 6 month follow-up.

Imaging versus Urinary Function Patient-Reported Outcome Measure (PROM).

Time frame
From surgery (day 0) and at the 6-month follow-up (day 180).
2

Assessment of the feasibility of augmented reality using tractography-based 3D model.

To document the feasibility of augmented reality using a tractography model (operative time).

Time frame
At surgery (day 0)
3

3. Concordance of pre- and postoperative Diffusion Tensor Imaging.

Evolution of nerve integrity after surgery

Time frame
At the end of the 6-month follow-up (day 180)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Massimo Valerio

Lead sponsor

University Hospital, Geneva

Sponsor institution

University of Geneva, Switzerland

Collaborator